JP2007520566A - 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法 - Google Patents

自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法 Download PDF

Info

Publication number
JP2007520566A
JP2007520566A JP2006552302A JP2006552302A JP2007520566A JP 2007520566 A JP2007520566 A JP 2007520566A JP 2006552302 A JP2006552302 A JP 2006552302A JP 2006552302 A JP2006552302 A JP 2006552302A JP 2007520566 A JP2007520566 A JP 2007520566A
Authority
JP
Japan
Prior art keywords
antigen
antibody
cells
autoantigen
self
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520566A5 (enExample
Inventor
ケヴァン ヘロルド
ヘラート マティアス フォン
ジェフリー エイ ブルーストーン
Original Assignee
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク
ザ ラ ジョラ インスティテュート フォア アラージー アンド イミュノロジー
ユーシーエスエフ ダイアビーティズ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク, ザ ラ ジョラ インスティテュート フォア アラージー アンド イミュノロジー, ユーシーエスエフ ダイアビーティズ センター filed Critical ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク
Publication of JP2007520566A publication Critical patent/JP2007520566A/ja
Publication of JP2007520566A5 publication Critical patent/JP2007520566A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2006552302A 2004-02-04 2005-02-04 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法 Pending JP2007520566A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195904P 2004-02-04 2004-02-04
PCT/US2005/003712 WO2005076965A2 (en) 2004-02-04 2005-02-04 Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity

Publications (2)

Publication Number Publication Date
JP2007520566A true JP2007520566A (ja) 2007-07-26
JP2007520566A5 JP2007520566A5 (enExample) 2008-03-27

Family

ID=34860238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552302A Pending JP2007520566A (ja) 2004-02-04 2005-02-04 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法

Country Status (7)

Country Link
US (1) US20070190045A1 (enExample)
EP (1) EP1725254A4 (enExample)
JP (1) JP2007520566A (enExample)
AU (1) AU2005213449A1 (enExample)
CA (1) CA2554978A1 (enExample)
IL (1) IL177193A0 (enExample)
WO (1) WO2005076965A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528043A (ja) * 2005-02-04 2008-07-31 ダウ・アグロサイエンシーズ・エルエルシー 抗ｔ細胞および自己免疫疾患の自己抗原治療
JP2013508392A (ja) * 2009-10-20 2013-03-07 グラクソ グループ リミテッド 自己免疫疾患における抗ｃｄ３抗体の投薬

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20050004001A1 (en) * 2002-10-02 2005-01-06 Robert Harris Formulation of antigen
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
SG177944A1 (en) * 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
BRPI0615745A2 (pt) * 2005-09-12 2011-05-24 Novimmune Sa formulação de anticorpo anti-cd3
ES2596855T3 (es) 2005-11-29 2017-01-12 Intrexon Actobiotics Nv Inducción de tolerancia mucosa a antígenos
WO2007084775A2 (en) * 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
AU2007260687B2 (en) * 2006-06-14 2013-12-12 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2094302A4 (en) * 2006-12-21 2010-12-08 Macrogenics Inc METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
JP2010516269A (ja) 2007-01-25 2010-05-20 アクトジェニックス・エヌブイ 抗原の粘膜送達による免疫疾患の治療
RU2009143345A (ru) * 2007-04-24 2011-05-27 Диамид Терапьютикс Аб (Se) Лекарственные средства и способы для лечения аутоиммунного заболевания и рака
JP2013517329A (ja) * 2010-01-20 2013-05-16 ベイヒル セラピューティクス インコーポレーティッド 自己免疫疾患を処置するための併用治療
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
CN106668852B (zh) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
GB201510056D0 (en) * 2015-06-10 2015-07-22 King S College London Multi-peptide composition
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2018315052B2 (en) * 2017-08-07 2025-01-02 St Vincent's Institute Of Medical Research Type 1 diabetes therapy
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028441A1 (en) * 2001-10-02 2003-04-10 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497883B1 (en) * 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
US6406696B1 (en) * 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028441A1 (en) * 2001-10-02 2003-04-10 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528043A (ja) * 2005-02-04 2008-07-31 ダウ・アグロサイエンシーズ・エルエルシー 抗ｔ細胞および自己免疫疾患の自己抗原治療
JP2013508392A (ja) * 2009-10-20 2013-03-07 グラクソ グループ リミテッド 自己免疫疾患における抗ｃｄ３抗体の投薬

Also Published As

Publication number Publication date
EP1725254A4 (en) 2008-02-13
WO2005076965A3 (en) 2006-07-06
WO2005076965A2 (en) 2005-08-25
CA2554978A1 (en) 2005-08-25
EP1725254A2 (en) 2006-11-29
AU2005213449A1 (en) 2005-08-25
IL177193A0 (en) 2006-12-10
US20070190045A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
JP2007520566A (ja) 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
Bresson et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
JP3007977B2 (ja) 抗原特異的なｔ細胞寛容の誘導方法
RU2540018C2 (ru) Средство для лечения заболевания
EP1421191B1 (en) Humanised antibodies specific for both CD45RB and CD45RO
You et al. Transforming growth factor‐β and T‐cell‐mediated immunoregulation in the control of autoimmune diabetes
US20220411510A1 (en) Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
MX2010010028A (es) Agente para tratar enfermedad.
JP2015120724A (ja) ＩＣＯＳ陽性細胞のｉｎｖｉｖｏ枯渇によるＴ細胞介在病態の治療方法
US20090232854A1 (en) Uses of bispecific antibody coated dendritic cells pulsed with antigens and gm-csf in immune regulation
US20070190052A1 (en) Regulatory CD8cells induced with anti-CD3 antibody
Burns et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance
Chatenoud et al. Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse
US20210236512A1 (en) Clozapine for the treatment of a immunoglobulin driven b cell disease
WO2021019249A1 (en) Clozapine for use in treating pathogenic immunoglobulin driven b cell disease
US20240228654A9 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
WO2009105548A2 (en) Methods for treating diabetes
Berrih-Aknin et al. Vaccines against myasthenia gravis
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体
Firdessa-Fite et al. Soluble antigen arrays improve the efficacy and safety of peptide-based tolerogenic immunotherapy
Ng et al. From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic
Smith An Investigation of Oral Tolerance and Priming in Vivo
Vanasek Cell cycle progression regulates in vivo clonal anergy induction
Forman et al. Immune Privilege and Tolerance–Therapeutic Antibody Approaches
Graça Mechanisms of peripheral tolerance in transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110905